Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
11.10 x 3 13.61 x 1
Post-market by (Cboe BZX)
13.00 +0.08 (+0.62%) 04/23/25 [NASDAQ]
11.10 x 3 13.61 x 1
Post-market 13.00 unch (unch) 16:15 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
12.81
Day High
13.59
Open 13.35
Previous Close 12.92 12.92
Volume 1,342,692 1,342,692
Avg Vol 1,988,910 1,988,910
Stochastic %K 83.35% 83.35%
Weighted Alpha -34.29 -34.29
5-Day Change +1.67 (+14.74%) +1.67 (+14.74%)
52-Week Range 9.66 - 25.07 9.66 - 25.07
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,111,688
  • Shares Outstanding, K 86,044
  • Annual Sales, $ 23,680 K
  • Annual Income, $ -318,760 K
  • EBIT $ -339 M
  • EBITDA $ -352 M
  • 60-Month Beta 1.28
  • Price/Sales 43.35
  • Price/Cash Flow N/A
  • Price/Book 3.53

Options Overview Details

View History
  • Implied Volatility 79.92% ( -20.07%)
  • Historical Volatility 74.93%
  • IV Percentile 84%
  • IV Rank 45.75%
  • IV High 144.90% on 04/10/25
  • IV Low 25.12% on 06/04/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 757
  • Volume Avg (30-Day) 854
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 30,988
  • Open Int (30-Day) 26,703

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.05
  • Number of Estimates 6
  • High Estimate -1.00
  • Low Estimate -1.13
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.66 +34.58%
on 04/09/25
Period Open: 13.71
13.97 -6.94%
on 03/24/25
-0.71 (-5.18%)
since 03/21/25
3-Month
9.66 +34.58%
on 04/09/25
Period Open: 14.41
16.95 -23.30%
on 02/21/25
-1.41 (-9.78%)
since 01/23/25
52-Week
9.66 +34.58%
on 04/09/25
Period Open: 20.97
25.07 -48.15%
on 07/26/24
-7.97 (-38.01%)
since 04/23/24

Most Recent Stories

More News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX : 13.00 (+0.62%)
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

SNDX : 13.00 (+0.62%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX : 13.00 (+0.62%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 13.00 (+0.62%)
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

SNDX : 13.00 (+0.62%)
Syndax Announces Participation in March Investor Conferences

SNDX : 13.00 (+0.62%)
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

SNDX : 13.00 (+0.62%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 31.69 (-1.55%)
JNJ : 155.38 (-1.50%)
VRTX : 492.42 (+0.40%)
SNDX : 13.00 (+0.62%)
ABBV : 177.05 (+1.88%)
GERN : 1.3900 (-1.42%)
RHHBY : 39.1400 (+0.41%)
PFE : 22.39 (-0.62%)
NTLA : 8.09 (-2.65%)
BMY : 48.53 (-2.59%)
BIIB : 118.17 (-0.61%)
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

The recent advancements in their pipelines imply high growth potential in the coming years.

ZVRA : 7.25 (-0.82%)
RPRX : 31.69 (-1.55%)
SNDX : 13.00 (+0.62%)
INCY : 58.00 (+1.08%)
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.5666 (-5.57%)
IOVA : 3.19 (-0.62%)
SNDX : 13.00 (+0.62%)
ONC.TO : 0.79 (-5.95%)
IBRX : 2.69 (unch)
SWTX : 41.21 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 14.24
2nd Resistance Point 13.91
1st Resistance Point 13.46
Last Price 13.00
1st Support Level 12.68
2nd Support Level 12.35
3rd Support Level 11.90

See More

52-Week High 25.07
Fibonacci 61.8% 19.18
Fibonacci 50% 17.36
Fibonacci 38.2% 15.55
Last Price 13.00
52-Week Low 9.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective